EXELExelixisRunning, no new patients
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.5
3 insiders sold shares within a month
Since May 26, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 2/3
- Patients
- 600 (planned)
- Started
- Jun 7, 2024
- Main results expected
- Aug 2028
- Fully finished
- Mar 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)
Measured over: Approximately 33 months after the first subject is randomized
Overall Survival (OS)
Measured over: Approximately 50 months after the first subject is randomized
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.5, since 2026-05-26, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06082167 · record last updated 2025-08-17 · checked 2026-11-09 15:47 UTC